Bright Minds Biosciences (DRUG) Operating Income (2023 - 2024)

Bright Minds Biosciences (DRUG) posted Operating Income of $32422.2 for Q4 2024, down 79.37% on a QoQ basis from $157133.8 in Q2 2024, and up 102.62% year-over-year from $16001.4 in Q1 2024.

Bright Minds Biosciences (DRUG) Operating Income (2023 - 2024) Analysis & Trends

Bright Minds Biosciences' Operating Income history runs 2 years deep, the most recent figure standing at $32422.2 for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -27.75 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -15.76 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 249.90 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.14 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 642.90 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -32.68 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 394.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -445.22 Mn
10 Bright Minds Biosciences 681.98 Mn 681.98 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 32,422.24
Jun 30, 2024 157,133.80
Dec 31, 2023 -1.24 Mn
Jun 30, 2023 -1.09 Mn